First Trust Advisors’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $27.1M | Sell |
51,089
-13,588
| -21% | -$6.27M | 0.02% | 852 |
|
|
2026
Q1 | $31.1M | Sell |
64,677
-3,008
| -4% | -$1.54M | 0.02% | 764 |
|
|
2025
Q4 | $38M | Buy |
67,685
+57,861
| +589% | +$32.8M | 0.03% | 675 |
|
|
2025
Q3 | $5.05M | Sell |
9,824
-32,395
| -77% | -$14.1M | ﹤0.01% | 1371 |
|
|
2025
Q2 | $13.3M | Buy |
42,219
+21,641
| +105% | +$6.5M | 0.01% | 1006 |
|
|
2025
Q1 | $6.27M | Sell |
20,578
-23,988
| -54% | -$8.07M | 0.01% | 1212 |
|
|
2024
Q4 | $14.8M | Sell |
44,566
-63,229
| -59% | -$21.4M | 0.01% | 949 |
|
|
2024
Q3 | $36M | Sell |
107,795
-871
| -0.8% | -$331K | 0.03% | 614 |
|
|
2024
Q2 | $44.8M | Sell |
108,666
-19,065
| -15% | -$7.55M | 0.05% | 537 |
|
|
2024
Q1 | $51.6M | Sell |
127,731
-32,229
| -20% | -$11.3M | 0.05% | 456 |
|
|
2023
Q4 | $49M | Sell |
159,960
-7,140
| -4% | -$1.93M | 0.05% | 441 |
|
|
2023
Q3 | $40.5M | Buy |
167,100
+136,434
| +445% | +$34.9M | 0.05% | 476 |
|
|
2023
Q2 | $7.37M | Sell |
30,666
-19,928
| -39% | -$4.14M | 0.01% | 1091 |
|
|
2023
Q1 | $9.51M | Buy |
50,594
+4,162
| +9% | +$861K | 0.01% | 1004 |
|
|
2022
Q4 | $9.86M | Buy |
46,432
+13,168
| +40% | +$2.63M | 0.01% | 962 |
|
|
2022
Q3 | $5.23M | Buy |
33,264
+29,760
| +849% | +$4.75M | 0.01% | 1169 |
|
|
2022
Q2 | $524K | Sell |
3,504
-25,720
| -88% | -$3.72M | ﹤0.01% | 2188 |
|
|
2022
Q1 | $4.78M | Sell |
29,224
-75,180
| -72% | -$12.4M | ﹤0.01% | 1349 |
|
|
2021
Q4 | $22.7M | Sell |
104,404
-30,205
| -22% | -$6.32M | 0.02% | 795 |
|
|
2021
Q3 | $25.5M | Sell |
134,609
-25,509
| -16% | -$4.65M | 0.03% | 689 |
|
|
2021
Q2 | $28.3M | Buy |
160,118
+30,181
| +23% | +$5.21M | 0.03% | 634 |
|
|
2021
Q1 | $21.3M | Buy |
129,937
+35,046
| +37% | +$5.36M | 0.03% | 687 |
|
|
2020
Q4 | $13.2M | Buy |
94,891
+4,863
| +5% | +$613K | 0.02% | 756 |
|
|
2020
Q3 | $10.1M | Sell |
90,028
-13,296
| -13% | -$1.54M | 0.02% | 731 |
|
|
2020
Q2 | $9.61M | Sell |
103,324
-10,997
| -10% | -$936K | 0.02% | 760 |
|
|
2020
Q1 | $8.39M | Buy |
114,321
+6,503
| +6% | +$565K | 0.02% | 704 |
|
|
2019
Q4 | $9.06M | Buy |
107,818
+19,480
| +22% | +$1.51M | 0.02% | 872 |
|
|
2019
Q3 | $7.42M | Buy |
88,338
+27,365
| +45% | +$2.07M | 0.01% | 906 |
|
|
2019
Q2 | $3.99M | Sell |
60,973
-6,692
| -10% | -$386K | 0.01% | 1192 |
|
|
2019
Q1 | $3.99M | Sell |
67,665
-42,633
| -39% | -$2.55M | 0.01% | 1151 |
|
|
2018
Q4 | $5.84M | Sell |
110,298
-57,861
| -34% | -$3.18M | 0.01% | 916 |
|
|
2018
Q3 | $10.1M | Buy |
168,159
+101,977
| +154% | +$5.58M | 0.02% | 838 |
|
|
2018
Q2 | $2.85M | Buy |
+66,182
| New | +$2.67M | 0.01% | 1418 |
|
|
2018
Q1 | – | Sell |
-42,608
| Closed | -$1.54M | – | 2349 |
|
|
2017
Q4 | $1.54M | Buy |
+42,608
| New | +$1.49M | ﹤0.01% | 1664 |
|
|
2017
Q1 | – | Sell |
-24,120
| Closed | -$870K | – | 2428 |
|
|
2016
Q4 | $870K | Buy |
+24,120
| New | +$803K | ﹤0.01% | 1901 |
|
Other funds holding MEDP
WA
First Trust Advisors's MEDP Position: Q2 2026 in Review
First Trust Advisors reduced its Medpace (MEDP) stake by 21% in Q2 2026, selling an estimated $6.27M and leaving 51,089 shares worth $27.1M. The position accounts for 0.02% of the portfolio, ranked #852.
First Trust Advisors first reported a position in MEDP in Q4 2016 and has held it in 35 quarters since. The position peaked at $51.6M in Q1 2024. 694 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- First Trust Advisors held 51,089 shares of Medpace worth $27.1M as of Q2 2026.
- First Trust Advisors sold 13,588 Medpace shares in Q2 2026, an estimated $6.27M.
- Medpace made up 0.02% of First Trust Advisors's portfolio in Q2 2026, its #852 holding.
- First Trust Advisors first reported a position in Medpace in Q4 2016 and has held it in 35 quarters since.
- First Trust Advisors's Medpace position peaked at $51.6M in Q1 2024.
- 694 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.